Daniel Ojeda
WRITTEN BY Daniel Ojeda
HitGen Ink Deal with Cambridge Molecular to Create a Deep Learning-Driven Drug Discovery Platform
2021-11-08
AC Immune’s Stock Climbs Following Mixed Phase 2 Trial Results for Alzheimer’s Disease Drug
2021-09-01